Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
245.6 EUR | -0.14% | -.--% | -.--% |
02:32pm | Roche: positive CHMP opinion for Alecensa | CF |
01:58pm | Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU | MT |
Sales 2024 * | 60.04B 65.68B 61.39B | Sales 2025 * | 63.83B 69.83B 65.27B | Capitalization | 176B 193B 180B |
---|---|---|---|---|---|
Net income 2024 * | 13.31B 14.56B 13.61B | Net income 2025 * | 14.75B 16.14B 15.08B | EV / Sales 2024 * | 3.17 x |
Net Debt 2024 * | 14.24B 15.58B 14.56B | Net Debt 2025 * | 8.17B 8.93B 8.35B | EV / Sales 2025 * | 2.89 x |
P/E ratio 2024 * |
12.9
x | P/E ratio 2025 * |
11.7
x | Employees | 103,605 |
Yield 2024 * |
4.44% | Yield 2025 * |
4.6% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | -0.14% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 65 | 95-12-31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.16% | 653B | |
+27.00% | 556B | |
-6.69% | 354B | |
+20.83% | 331B | |
+2.16% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-5.99% | 144B | |
-11.39% | 143B |
- Stock Market
- Equities
- ROG Stock
- RHO5 Stock